Medical Markets:

Business Communications Company Inc.
Market Study  December 2005

INTRODUCTION

In March 2002, BCC published its first study focused on stem cells and progenitor cell therapy. Since that time, stem cell and regenerative companies have had a difficult time because of a shortage of funding. However, new companies have sprung up, as new research prompts new avenues of exploration. The political climate for embryonic stem cells has changed. The Bush Administration maintains a ban in the U.S. on federal funding for research using newly established lines. However, California and Illinois have begun funding this research and others seem likely to follow. The House of Representatives has passed a bill reversing Bush’s ban, and the Senate is likely to pass it. Meanwhile, other countries are making embryonic stem cell research a priority. Given these many changes, it seems a good time to renew our study of the field. This comprehensive and cohesive technical market research report from BCC is set within the existing regulatory framework and takes into account not only technical accomplishments but also political and financial realities. The study, therefore, establishes the necessary context from which to make rational decisions regarding business decisions in this expanding field.

SCOPE OF STUDY

The report contains:

* An overview that introduces the various kinds of stem cells, gives definitions, and discusses political and regulatory aspects

* Analysis of applications including current and potential cytokine and cell therapies with forecasts through 2010

*A discussion of current products as well as many that are still in clinical trials

*An industry structure analysis including companies in the field and their focus

*Profiles of individual companies, and includes the names of key officers.

REPORT HIGHLIGHTS

* The worldwide market for stem cell, cytokine and growth factor therapies is estimated at $12.7 billion in 2005 and, rising at an average annual growth rate (AAGR) of 10.3%, is expected to reach $20.7 billion in 2010.

* Nearly 98% of the market is consumed by blood and immune system treatments, a figure that will shrink slightly to 95% in 2010.

* Revenues worldwide for stem cell, cytokine and growth factor therapies for all other bodily systems are expected to rise at an AAGR of 26.4% to just over $1 billion in 2010.

* The first off-the-shelf cell therapy approved by the FDA was for wound treatment. Recently, a bone morphogenic protein (BMP) has been approved for the acceleration of spinal fusions.

For full details, please email jenniferc@cmsinfo.com

Order Form

For more information about us, visit CMSinfo.